Quantum BioPharma is trading 6.58% down now at $3.55, with the decline remaining unexplained.

  • It opened August 17, 2026 below the August 14 close of $3.80; no new company-specific negative catalyst was identified.
  • Recent coverage highlights the FDA’s August 10 clearance for Lucid-MS to advance into a Phase 2 multiple-sclerosis trial.
  • The August 14 Q2 update reported approximately US$9.5 million in liquidity; profit-taking remains possible but unconfirmed.